TY - JOUR AU - Yoshiji, Hitoshi AU - Noguchi, Ryuichi AU - Ikenaka, Yasuhide AU - Namisaki, Tadashi AU - Kitade, Mitsuteru AU - Kaji, Kosuke AU - Shirai, Yusaku AU - Yoshii, Junichi AU - Yanase, Koji AU - Yamazaki, Masaharu AU - Tsujimoto, Tatsuhiro AU - Kawaratani, Hideto AU - Akahane, Takemi AU - Aihara, Yosuke AU - Fukui, Hiroshi PY - 2009 DA - 2009/05/05 TI - Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat JO - BMC Research Notes SP - 70 VL - 2 IS - 1 AB - Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical practice. To find out promising new therapeutic agents, it is important to employ an appropriate experimental model of NASH, such as association with insulin resistance. SN - 1756-0500 UR - https://doi.org/10.1186/1756-0500-2-70 DO - 10.1186/1756-0500-2-70 ID - Yoshiji2009 ER -